Proprietary Real-time Thrombosis Detection
Fast, specific and accurate. Highly sensitive especially at the early stage. Real-time monitoring of thrombosis for precison medicine.
Early Diagnosis of Sepsis
Patented biomarker reaches its peak within 2 hours (vs 24-48 hours, PCT & CRP) therefore detect sepsis at a much earlier stage for more timely treatment.
Drug Candidate for Sepsis
Our drug candidate can reduce >90% mortality rates in animal studies (LPS-Induced Sepsis Rodent Models) and will soon enter the IND stage.
Biotech Innovation + Digital Technology
01. Accurate & Conclusive
Unlike other biomarkers that only indicate a hypercoagulable state or indirectly measure thrombus degradation products, our biomarkers directly reflect the formation and stabilization of thrombus, so the results are more accurate and reliable.
02. Real-time Monitoring
World's 1st technology capable of monitoring thrombosis in real-time. Not only does it evaluate the severity and prognosis, but also guides subsequent anticoagulation or thrombolytic treatments for precision medicine.
03. Big Data Powered by AI
Unique data generated from our proprietary biomarkers + AI-powered data analysis will help us continuously improve the accuracy of diagnosis and provide a cost-effective way of disease prevention and CVD management.
Self-test for CVD Management
Safeguard Health
Anytime Anywhere
Like a blood glucose meter, our "thrombosis meter" is portable, cost-effective, and easy to use. Continuously monitoring thrombosis risk is now possible and we create a blue ocean for CVD management.
Detect even before Symptons Occur
Clinical studies show that our biomarker is elevated in a very early stage, even before symptoms appear. Therefore it is expected to be the first technology for effective prediction and early diagnosis of thrombosis.
1 in 4
of all deaths worldwide are as a result of thrombosis. More than 80% of which are preventable. (Lancet)
>20%
deaths are associated with sepsis.
1-hour treatment delay will increase the risk of death by 8%. (WHO)
3+1
3 proprietary biomarkers for thrombosis and sepsis diagnosis + 1 drug candidate for sepsis treatment.
35.3
billion USD total accessible market (TAM) for thrombosis and sepsis early diagnosis and treatment.
